Browse News
Filter News
Found 764,061 articles
-
Top Biotech Licensing Deals of Q1 2023
3/30/2023
There have already been several big biotech licensing deals in Q1. See inside for some of this quarter's biggest licensing deals — from the surprising and pivotal to the lucrative and consequential. -
Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock - March 30, 2023
3/30/2023
Biomea Fusion, Inc. announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $30.00 per share.
-
Delcath Systems Announces Closing of Private Placement of up to $85 Million
3/30/2023
Delcath Systems, Inc. announces that it has closed its previously announced private placement, for gross proceeds of approximately $25.0 million from the issuance and sale of shares of the Company's common stock and shares of its Series F Convertible Preferred Stock and warrants, before deducting the fees paid to the placement agent and the financial advisors of the Private Placement and other financing expenses payable by the Company.
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
3/30/2023
Avadel Pharmaceuticals plc announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2022.
-
Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
3/30/2023
Avadel Pharmaceuticals plc announced the pricing of an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per share in the form of American Depositary Shares and of 4,705,882 Series B Non-Voting Convertible Preferred Shares, convertible into Ordinary Shares on a one-for-one basis.
-
Lytix Biopharma: Annual Report for 2022
3/30/2023
Lytix Biopharma AS announces that it has published its Annual Report for 2022, which was approved by the board of directors on March 29, 2023.
-
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022
3/30/2023
Poolbeg Pharma Plc a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022.
-
ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China
3/30/2023
ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration for Phase I clinical trial in China on March 29, 2023.
-
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
3/30/2023
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the pricing of its underwritten public offering of 17,242,000 shares of its common stock at a price to the public of $14.50 per share.
-
Sensorion Announces the Publication of Its 2022 Annual Financial Report
3/30/2023
Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that its Annual Financial Report for the year ending December 31, 2022, is available to the public and filed with the French financial market authority.
-
ONWARD Publishes First Annual ESG Summary
3/30/2023
ONWARD Medical N.V., the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, publishes its first Annual ESG Summary.
-
Press Release: Availability of the Q1 2023 Memorandum for modelling purposes
3/30/2023
Sanofi announced that its Q1 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website.
-
AMWC 2023: Data From Sculptra® Cheek Wrinkle and Alluzience® Star Studies Reinforce Strength of Galderma’s Broad Aesthetic Portfolio
3/30/2023
Galderma will be presenting the latest data from the Sculptra® Cheek Wrinkle and Alluzience® STAR studies at the 21st Aesthetic & Anti-Aging Medical World Congress, taking place in Monaco, from March 30 to April 1, 2023.
-
Addex Reports Full Year 2022 Financial Results and Provides Corporate Update
3/30/2023
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported financial results for the full-year ended December 31, 2022, and provided a corporate update.
-
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.
3/30/2023
Valneva SE, a specialty vaccine company, announced it will present on its single-shot chikungunya vaccine candidate, VLA1553, and host a roundtable on Zika vaccines next week at the 23rd World Vaccine Congress in Washington, D.C.
-
FDA approves Bioretec's RemeOs™ trauma screw as the first bioresorbable metal implant in the U.S. market
3/30/2023
Bioretec Ltd. has received market authorization for its RemeOs™ trauma screw in the U.S. The RemeOs™ trauma screw is the first and currently only bioresorbable metal implant approved by the U.S. Food and Drug Administration.
-
Citing reports of “alarming toxicity” among other accusations, short-seller Scorpion Capital will file a Citizen’s Petition with the FDA to have its approval of Wakix withdrawn.
-
Intra-Cellular Therapies’ Caplyta met its primary endpoint in the Phase III Study 403 trial, easing the burden of depressive episodes in patients with major depressive disorder or bipolar depression.
-
Tuesday, Viking Therapeutics released Phase I results for its weight-loss candidate VK2735, which demonstrated a good safety and tolerability profile and resulted in significant weight reductions.
-
Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1.